KRAS-targeted therapy extends life in pancreatic cancer, signaling a new era
TL;DR
A pancreatic cancer patient on Revolution Medicines' KRAS inhibitor daraxonrasib reports a dramatic extension of life, illustrating how targeting historically 'undruggable' KRAS can yield durable benefits and fueling optimism for KRAS inhibitors across pancreatic and other KRAS-mutant cancers.
Topics:businesshealth#clinical-trials#health#kras#pancreatic-cancer#revolution-medicines#targeted-therapy
Want the full story? Read the original reporting
Read on statnews.com